You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel multi-sensing seat cover system for prevention of sitting-related pressure injuries in individuals with Alzheimer's disease or related dementias
SBC: Adapt Design Works, LLC Topic: NIAABSTRACT The long-term objective of this project is to create a sensor-based monitoring technology for use by caregivers, clinicians, and individuals living with Alzheimer’s disease or Alzheimer’s disease related dementia (AD/ADRD) to mitigate the risk of pressure injuries related to prolonged sitting. Pressure injury prevalence is disproportionately high in the aging AD/ADRD population due to ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease
SBC: Metselex, Incorporated Topic: 105ABSTRACT This Phase STTR Phase II proposal aims to engineer and scale-up a synthetic metabolic pathway in a microbial host to produce UDCA and related compounds. Additionally, the UDCA produced from the engineered synthetic metabolic pathway will be used to synthesize derivatives for testing in our Alzheimer’s Disease cell and animal models. The proposed work has high intellectual merit for the ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells
SBC: MARPAM PHARMA LLC Topic: NIAIDProject Summary MarPam Pharma aims to develop a one-time treatment for achieving durable remission of human immunodeficiency virus (HIV), after which patients will no longer need to take antiretroviral therapy. Our treatment is an autologous HIV-specific chimeric antigen receptor (CAR) immune cell therapy that employs the CXCR5 chemokine receptor as a homing device to direct either anti-HIV T cell ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
MTI-301 a SCD1 inhibitor for the treatment of NASH
SBC: MODULATION THERAPEUTICS, INC. Topic: 300Abstract: Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in children and adults associated with diet-associated hepatic lipid accumulation (steatosis), and is a common hepatic manifestation of obesity and metabolic syndromes including diabetes. Modulation Therapeutics is developing a stearoyl- coenzyme A desaturase-1 (SCD1) inhibitor for the treatment of NAFLD a ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Two-for-one Stroke Thrombectomy:A novel Dual DAC to enhance navigability, lumen size, aspiration efficiency, and persistent flow arrest in mechanical thrombectomy
SBC: PIRAEUS MEDICAL, INC. Topic: 105PROJECT SUMMARY/ABSTRACT The long-term goal of this proposal is to improve the care of patients suffering from Large Vessel Occlusion Acute Ischemic stroke. Currently, mechanical thrombectomy techniques can achieve revascularization in over 70% of cases, and physicians are rapidly adoption aspiration thrombectomy over stent-trievers. Aspiration maintains equivalent angiographic and clinical outcom ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
GENOMICE (Game Exploring Nuances in Offspring to Master Interactions of Chromosome Expression)
SBC: SMART INFORMATION FLOW TECHNOLOGIES LLC Topic: NHGRIPROJECT SUMMARY Genomics has become an essential element of biomedical science, playing multiple roles in rapidly addressing the COVID-19 pandemic, understanding medical complications to develop more effective preventative care and treatments, and modeling diseases in laboratory specimens for study. Despite the increasing relevance of genomics to people's everyday lives, genomics literacy in the U ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Prodrugs of potent and selective protease inhibitors as tauopathy therapeutics
SBC: MYRIEL, INC. Topic: 105PROJECT ABSTRACT Myriel, Inc., is a pharmaceutical start-up company founded in 2022 to find cures for tauopathies, including Alzheimer’s disease and related dementias (ADRD), which impair cognition in 32% of US adults 65 years and older. The goal of this Phase 1 STTR application is to provide Myriel with a brain-penetrant analogue of our lead compound, GPHR ‘739, the first potent, selective, r ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD
SBC: MYOGENICA INC. Topic: NIAMSPROJECT SUMMARY Duchenne muscular dystrophy (DMD) is the most common type of muscular dystrophy, caused due to mutations in the dystrophin gene. DMD is characterized by progressive muscle wasting and overall loss of muscle function. DMD patients become wheel chair dependant by 12 years of age and the associated cardiorespiratory complications result in their early death around 20 years of age. Dys ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform
SBC: Trekka Therapeutics, LLC Topic: NCIAbstract Despite the dramatic improvement in outcomes afforded by immune checkpoint inhibitors and targeted therapies, most patients with metastatic BRAF-mutated melanoma ultimately experience progression of their disease. One key reason for resistance to immune checkpoint inhibitors is a paucity of melanoma-specific T cells, but unfortunately, the majority of early melanoma vaccines meant to expa ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Expansion and validation of novel mobile app for guiding home modifications for aging in place
SBC: HomesRenewed Ventures LLC Topic: RPROJECT SUMMARY In this Phase II SBIR, HomesRenewed Ventures, LLC (HRV Washington, DC) will build on our previous efforts to expand and validate an interactive mobile application (APP) for guiding home modifications (environmental interventions) critical to Aging in Place (AiP). Home modifications (HM) are associated with falls preventions, improved activities of daily living (ADLs), and emotional ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health